QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term GelrinC(R) Imaging Data Demonstrating Native-Like Cartilage Regeneration
Regentis Biomaterials (NYSE American: RGNT) announced new long-term imaging data from its completed European clinical trial of GelrinC(R), showing regenerated cartilage with internal structural organization closely resembling healthy native hyaline cartilage. Published in the peer-reviewed journal Cartilage, the MRI-based analysis demonstrated progressive tissue maturation over 24 months, with repaired cartilage exhibiting layered architecture comparable to native tissue, supporting GelrinC(R)’s potential to deliver durable cartilage regeneration and long-term joint function. To view the full press release, visit https://ibn.fm/rEL4F About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance…